ACCEL Lite: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

While we know that statin treatment reduces the risk of stroke, heart attack and heart deaths in people at moderate-to-high risk, or with high cholesterol, in REPRIEVE statins decreased the risk in those at low-to-moderate risk, and with 'normal' cholesterol levels who would not usually be considered candidates for treatment.

In this interview, Pamela S. Douglas, MD, MACC, and Roger S. Blumenthal MD, FACC, discuss Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

Related References:

  1. Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, M.D., Foldyna B, Looby SE, Desvigne‑Nickens P, Alston‑Smith B, Leon‑Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaudo HJ, Douglas PS. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. Online July 23, 2023. doi: 10.1056/NEJMoa2304146

Clinical Topics: Arrhythmias and Clinical EP, Dyslipidemia, SCD/Ventricular Arrhythmias, Lipid Metabolism, Nonstatins, Heart Failure and Cardiomyopathies, Prevention, Stable Ischemic Heart Disease

Keywords: ACCELLite, HIV, Death, Sudden, Cardiac, Cholesterol

< Back to Listings